Join the Eczema group to help and get support from people like you.
Eczema News
Early Dog Exposure May Modify Genetic Effect on Atopic Eczema Risk
MONDAY, June 9, 2025 – Early-life dog exposure may modify the genetic effect of the single nucleotide variant rs10214237 on atopic eczema (AE) via IL7R, according to a study published online June 4...
Fido Might Protect Your Baby Against Eczema
THURSDAY, June 5, 2025 — Having a family dog might decrease a baby’s risk of developing eczema later in childhood, a new evidence review says. Specifically, exposure to canines appears to influence a ...
New AI Can Help Track Eczema
FRIDAY, May 23, 2025 – Eczema sufferers could soon find it easier to track their skin condition, via a newly developed AI that can assess severity using uploaded smartphone images. The AI...
AI Three-Item Severity Score Can ID Eczema From Patient-Uploaded Images
FRIDAY, May 23, 2025 – An artificial intelligence (AI) Three-Item Severity (TIS) score can identify eczema-affected areas and severity scores from user-uploaded images, according to a research...
AAP Updates Guidelines for Pediatric Atopic Dermatitis Management
MONDAY, May 19, 2025 – In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for the treatment of children with atopic dermatitis ...
Global Burden of Atopic Dermatitis in Older Adults Is Considerable
WEDNESDAY, May 7, 2025 – The global burden of atopic dermatitis (AD) in older adults is considerable and is expected to continue increasing to 2050, according to a study published online April 1 in...
Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis
WEDNESDAY, April 23, 2025 – Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published online April 3 in JAMA Ophthalmology. Yung-Yu ...
American Academy of Dermatology, March 7 to 11
The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health professionals, and others interested i...
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
FRIDAY, March 14, 2025 – Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in P...
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
FRIDAY, March 14, 2025 – Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off treatment,...
Early Childhood Stressful Life Events Linked to Increased Eczema Activity
WEDNESDAY, Feb. 5, 2025 – For children with atopic dermatitis (AD), early childhood stressful life events are associated with an increased risk for disease activity, according to a study published...
Study IDs Signs of Topical Steroid Withdrawal in Atopic Dermatitis
WEDNESDAY, Jan. 22, 2025 – Self-reported manifestations of topical steroid withdrawal (TSW) in atopic dermatitis (AD) include erythema, desquamation, dryness, and oozing affecting the face, neck,...
Who Knew Talk Therapy Could Ease Symptoms of this Skin Problem?
THURSDAY, Jan. 2, 2025 – Eczema can be maddening, causing thick, scaly patches of dry skin that itch like the devil. There’s no cure for the skin condition, but a new study shows that self-guided t...
FDA Expands Approval of Vtama to Include Atopic Dermatitis
THURSDAY, Dec. 19, 2024 – The U.S. Food and Drug Administration has approved Vtama (tapinarof) 1 percent cream for an additional indication – the topical treatment of atopic dermatitis in adult and...
FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Dec. 18, 2024 – The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older. ...
Further information
Related condition support groups
Related drug support groups
prednisone, methotrexate, clobetasol, Dupixent, fluocinonide, dexamethasone, desonide, dupilumab, halobetasol